MDXG Mimedx Group Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MDXG

Price (delayed)

$3.765

Market cap

$560.78M

P/E Ratio

17.93

Dividend/share

N/A

EPS

$0.21

Enterprise value

$418.6M

?
Relative Growth: Rel. Growth: 23
Relative Strength: Rel. Strength: 6
Relative Valuation: Rel. Valuation: 73
Relative Profitability: Rel. Profitability: 76

MiMedx is an industry leader in utilizing birth tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. ...

Highlights
The stock's price to earnings (P/E) is 25% less than its last 4 quarters average of 23.0
The quick ratio has increased by 23% QoQ and by 17% YoY
Mimedx Group's equity has increased by 20% YoY but it has decreased by 5% QoQ
MDXG's revenue is up by 11% YoY but it is down by 7% from the previous quarter
MDXG's net income is down by 37% QoQ and by 24% YoY
Mimedx Group's EPS has decreased by 36% QoQ and by 22% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.mimedx.com
Peers: MDT TFX ATEC STE

Key stats

What are the main financial stats of MDXG

MDXG stock price

How has the Mimedx Group stock price performed over time
Intraday
4.29%
1 week
2.59%
1 month
4.29%
1 year
-41.36%
YTD
-44.39%
QTD
-4.68%

Financial performance

How have Mimedx Group's revenue and profit performed over time
Revenue
$389.42M
Gross profit
$315.59M
Operating income
$39.57M
Net income
$30.7M
Gross margin
81%
Net margin
7.9%
The operating income fell by 38% QoQ and by 27% YoY
MDXG's net income is down by 37% QoQ and by 24% YoY
The operating margin has contracted by 33% from the previous quarter and by 33% YoY
The net margin has contracted by 32% from the previous quarter and by 31% YoY

Price vs fundamentals

How does MDXG's price correlate with its fundamentals

Growth

What is Mimedx Group's growth rate over time

Valuation

What is Mimedx Group stock price valuation
MDXG P/E details
P/E
17.93
P/B
2.3
P/S
1.44
EV/EBIT
10.49
EV/EBITDA
7.68
EV/Sales
1.07
Mimedx Group's EPS has decreased by 36% QoQ and by 22% YoY
The stock's price to earnings (P/E) is 25% less than its last 4 quarters average of 23.0
The P/B is 40% lower than the last 4 quarters average of 3.7
Mimedx Group's equity has increased by 20% YoY but it has decreased by 5% QoQ
The P/S is 47% lower than the 5-year quarterly average of 2.6 and 40% lower than the last 4 quarters average of 2.3
MDXG's revenue is up by 11% YoY but it is down by 7% from the previous quarter

Efficiency

How efficient is Mimedx Group business performance
Mimedx Group's return on equity has decreased by 40% YoY and by 39% QoQ
MDXG's ROA is down by 39% QoQ and by 39% YoY
MDXG's return on invested capital is down by 34% since the previous quarter and by 23% year-on-year
Mimedx Group's return on sales has decreased by 33% YoY and by 32% QoQ

Dividends

What is MDXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MDXG.

Financial health

How did Mimedx Group financials performed over time
The current ratio has increased by 25% since the previous quarter and by 15% year-on-year
The total liabilities has contracted by 24% from the previous quarter and by 2.8% YoY
The debt is 93% less than the equity
MDXG's debt to equity is down by 22% year-on-year
Mimedx Group's equity has increased by 20% YoY but it has decreased by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.